US EditionPublished • loading... • Updated
Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials
Summary by News Medical
1 Articles
1 Articles
Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials
Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
